BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260930T130000
DTEND;TZID=America/New_York:20260930T143000
DTSTAMP:20260925T204213
CREATED:20260824T182152Z
LAST-MODIFIED:20260924T173513Z
UID:3346-1790773200-1790778600@lifescievents.com
SUMMARY:Sagimet Biosciences Denifanstat Update: 52-Week Data from Open-Label Phase 3 Trial in China and Planned AURORA Phase 3 Clinical Trial in US
DESCRIPTION:Join Sagimet Biosciences for a virtual event featuring key opinion leader (KOL) Julie Harper\, MD\, Founding Director and past President of the American Acne and Rosacea Society. Dr. Harper will join Company management for a review of the 52-week data from license partner Ascletis’ open-label Phase 3 clinical trial of denifanstat in moderate to severe acne vulgaris in China (OLE)\, and an update on the Company’s planned AURORA Phase 3 clinical trial of denifanstat for the treatment of moderate to severe acne in the U.S. \nIn the OLE\, subjects treated with denifanstat showed improvements in all efficacy endpoints (secondary endpoints of the trial) beyond those observed at 12 weeks. Denifanstat was generally well tolerated throughout the trial. These results will be presented at the European Academy of Dermatology and Venereology Congress (EADV 2026)\, building on the topline results announced in February 2026. \nSagimet’s AURORA Phase 3 clinical trial of denifanstat in moderate to severe acne in the U.S. is expected to initiate in the fourth quarter of 2026. Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor with potential as a novel mechanism of action to address moderate to severe acne\, a condition that impacts more than 10 million people annually in the U.S. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/sdj928tn/.
URL:https://lifescievents.com/event/sdj928tn/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/08/Sagimet-Banner-1.png
END:VEVENT
END:VCALENDAR